Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: Caspase-8 and caspase-9 is associated with poor prognosis

International Journal of Cancer

Volumn 127, Issue 4, 2010, Pages 873-880

  Sträter, Jörn ^a,b   Herter, Ines ^b   Merkel, Gaby ^b   Hinz, Ulf ^c   Weitz, Jürgen ^c   Möller, Peter ^b  

^a Institute of Pathology   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

APAF 1; Caspase 8; Caspase 9; Colon carcinoma; Prognosis

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 8; CASPASE 9; APAF1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; COLLOID CARCINOMA; COLON; COLON TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; AGED; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CASPASE 8; CASPASE 9; COLON; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954731560     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25111     Document Type: Article

References (38)

1. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis system. Exp Cell Res 2000;256:58-66.
2. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-19.
3. Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med 2000;192:21-6.
4. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-7.
5. Graeber TG, Osmanian C, Jacks T, Lee JE, Giffard RG, DiPaolo JA, Peehl DM, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
6. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-14.
7. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153-64.
8. Möller P, Koretz K, Leithäuser F, Brüderlein S, Henne C, Quentmeier A, Krammer PH. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-7.
9. Tschopp J, Irmler M, Thome M. Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 1998;10:552-8.
10. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 2003;22:451-5.
11. Kim HS, Lee JW, Soung YH, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Jeong SW, Nam SW, Kim SH, et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 2003;125:708-15.
12. Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, Grotzer MA. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 2003;9:6401-9.
13. Zlobec I, Minoo P, Baker K, Haegert D, Khetani K, Tornillo L, Terracciano L, Jass JR, Lugli A. Loss of APAF-1 expression is associated with tumor progression and adverse prognosis in colorectal cancer. Eur J Cancer 2007;43:1101-7.
14. Paik SS, Jang K-S, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH, Choi D, Jang SJ. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol 2007;14:3453-9.
15. Sträter J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Möller P, Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: trail-R1 is an independent prognostic parameter. Clin Cancer Res 2002;8:3734-40.
16. Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma-clinical evidence for immunoselection and CD95L-mediated control of minimal residual disease. Gut 2005;54:661-5.
17. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of APAF-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 1998;58:4561-6.
18. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW. APAF-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999;284:156-9.
19. Wolf BB, Schuler M, Li W, Eggers-Sedlet B, Lee W, Tailor P, Fitzgerald P, Mills GB, Green DR. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 2001;276:34244-51.
20. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13:3191-7.
21. Martinez R, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007;28:1264-8.
22. Samaras V, Tsopanomichalou M, Stamatelli A, Arnaoutoglou C, Samaras E, Arnaoutoglou M, Poulias H, Barbatis C. Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal carcinomas? A comparative immunohistochemical analysis with clinical connotations. Diagn Pathol 2009;4:7.
23. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, Zeng C, Lin D. A six-nucleotide insertiondeletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007;39:605-13.
24. Muris JJF, Cillessen SAGM, Vos W, van Houdt IS, Kummer JA, van Krieken JH, Jiwa NM, Jansen PM, Kluin-Nelemans HC, Ossenkoppele GJ, Gundy C, Meijer CJ, et al. Immunohistcochemical profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005;105:2916-23.
25. Soung YH, Lee JW, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH. Mutational analysis of proapoptotic caspase-9 in common human carcinomas. APMIS 2006;114:292-7.
26. Xu B, Zhou ZG, Li Y, Wang L, Yang L, Zhou B, Liu HY, Song JM, Zeng YJ, Wang R, Shen XG, Sun XF. Clinicopathological significance of caspase-8 and caspase-10 in rectal cancer. Oncology 2008;74:229-36.
27. Heijink DM, Kleibeuker JH, Jalving M, Boersma-van Ek W, Koornstra JJ, Wesseling J, de Jong S. Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas. Cell Oncol 2007;29:409-19.
28. Finlay D, Vuori K. Novel noncatalytic role for caspase-8 in promoting Src-mediated adhesion and Erk signalling in neuroblastoma cells. Cancer Res 2007;67:11704-11.
29. Helfer B, Boswell BC, Finlay D, Cipres A, Vuori K, Bong Kang T, Wallach D, Dorfleutner A, Lahti JM, Flynn DC, Frisch SM. Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions. Cancer Res 2006;66:4273-8.
30. Senft J, Helfer B, Frisch SM. Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res 2007;67:11505-9.
31. Barbero S, Mielgo A, Torres V, Teitz T, Shields DJ, Mikolon D, Bogyo M, Barilà D, Lahti JM, Schlaepfer D, Stupack DG. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 2009;69:3755-63.
32. Finlay D, Howes A, Vuori K. Critical role for caspase-8 in epidermal growth factor signalling. Cancer Res 2009;69:5023-9.
33. Hubbard SR. EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 2005;7:287-8.
34. Papay J, Krenacs T, Moldvay J, Stelkovics E, Furak J, Molnar B, Kopper L. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach. Appl Immunohistochem Mol Morphol 2007;15:19-30.
35. Wang P, Shi T, Ma D. Cloning of a novel human caspase-9 splice variant containing only the CARD domain. Life Sci 2006;79:934-40.
36. Merkel S, Wein A, Günther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with stage II colon carcinoma. Cancer 2001;92:1435-43.
37. Merkel S, Mannsmann U, Papadopoulous T, Wittekind C, Hohenberger W, Hermanek P. The prognostic inhomogeneity of colorectal carcinomas stage III. A proposal for subdivision of stage III. Cancer 2001;92:2754-9.
38. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005;365:153-65.